A prognostication scoring system based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes could effectively predict the survival rate of RCC cancer patients (with a mean difference of four years in ccRCC). The gene discussed is RNASEH2A; the disease is renal cell carcinoma.